Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2010, Article ID 542691, 10 pages
http://dx.doi.org/10.1155/2010/542691
Research Article

Phosphorylated Neurofilament Heavy Chain Correlations to Visual Function, Optical Coherence Tomography, and Treatment

1Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, 1638 NW 10th Avenue, Miami, Fl 33136, USA
2Department of Neuroscience, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, FL 32610-0015, USA
3Department of Ophthalmology and Visual Sciences, the University of Iowa and Veterans Hospital, Iowa City, IA 52242, USA

Received 24 August 2010; Revised 22 November 2010; Accepted 14 December 2010

Academic Editor: Axel Petzold

Copyright © 2010 Joshua Pasol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. W. Beck, P. A. Cleary, M. M. Anderson Jr. et al., “A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis,” The New England Journal of Medicine, vol. 326, no. 9, pp. 581–588, 1992. View at Google Scholar
  2. C. Bjartmar, J. R. Wujek, and B. D. Trapp, “Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease,” Journal of the Neurological Sciences, vol. 206, no. 2, pp. 165–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Bjartmar, R. P. Kinkel, G. Kidd, R. A. Rudick, and B. D. Trapp, “Axonal loss in normal-appearing white matter in a patient with acute MS,” Neurology, vol. 57, no. 7, pp. 1248–1252, 2001. View at Google Scholar · View at Scopus
  4. G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri, “The contribution of demyelination to axonal loss in multiple sclerosis,” Brain, vol. 129, no. 6, pp. 1507–1516, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. F. Costello, S. Coupland, W. Hodge et al., “Quantifying axonal loss after optic neuritis with optical coherence tomography,” Annals of Neurology, vol. 59, no. 6, pp. 963–969, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. A. Trip, P. G. Schlottmann, S. J. Jones et al., “Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis,” Annals of Neurology, vol. 58, no. 3, pp. 383–391, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. A. Petzold, D. Baker, G. Pryce, G. Keir, E. J. Thompson, and G. Giovannoni, “Quantification of neurodegeneration by measurement of brain-specific proteins,” Journal of Neuroimmunology, vol. 138, no. 1-2, pp. 45–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, “Axonal transection in the lesions of multiple sclerosis,” The New England Journal of Medicine, vol. 338, no. 5, pp. 278–285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Shaw, C. Yang, R. Ellis et al., “Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury,” Biochemical and Biophysical Research Communications, vol. 336, no. 4, pp. 1268–1277, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Petzold and G. Shaw, “Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain,” Journal of Immunological Methods, vol. 319, no. 1-2, pp. 34–40, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. Petzold, “Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss,” Journal of the Neurological Sciences, vol. 233, no. 1-2, pp. 183–198, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Petzold, K. Rejdak, and G. T. Plant, “Axonal degenaration and inflammation in acute optic neuritis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 8, pp. 1178–1180, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. Petzold, M. J. Eikelenboom, G. Keir et al., “The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers,” Multiple Sclerosis, vol. 12, no. 3, pp. 325–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. L. Gal, “Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial,” American Journal of Ophthalmology, vol. 137, no. 1, pp. 77–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. R. W. Beck, “The optic neuritis treatment trial: three-year follow-up results,” Archives of ophthalmology, vol. 113, no. 2, pp. 136–137, 1995. View at Google Scholar · View at Scopus
  16. R. W. Beck, J. D. Trobe, P. S. Moke et al., “Visual function 5 years after optic neuritis: experience of the optic neuritis treatment trial,” Archives of Ophthalmology, vol. 115, no. 12, pp. 1545–1552, 1997. View at Google Scholar
  17. Optic Neuritis Study Group, “Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial,” Ophthalmology, vol. 115, no. 6, pp. 1079–1082, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. K. Boylan, C. Yang, J. Crook et al., “Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker,” Journal of Neurochemistry, vol. 111, no. 5, pp. 1182–1191, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. Huang, E. A. Swanson, C. P. Lin et al., “Optical coherence tomography,” Science, vol. 254, no. 5035, pp. 1178–1181, 1991. View at Google Scholar · View at Scopus
  20. J. S. Schuman, T. Pedut-Kloizman, E. Hertzmark et al., “Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography,” Ophthalmology, vol. 103, no. 11, pp. 1889–1898, 1996. View at Google Scholar · View at Scopus
  21. R. W. Beck, P. A. Cleary, J. D. Trobe et al., “The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis,” The New England Journal of Medicine, vol. 329, no. 24, pp. 1764–1769, 1993. View at Publisher · View at Google Scholar · View at PubMed
  22. C. E. Teunissen, E. Iacobaeus, M. Khademi et al., “Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis,” Neurology, vol. 72, no. 15, pp. 1322–1329, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Guy, G. Shaw, F. N. Ross-Cisneros et al., “Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON),” Molecular Vision, vol. 14, pp. 2443–2450, 2008. View at Google Scholar · View at Scopus
  24. M. M. Gresle, G. Shaw, B. Jarrott et al., “Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis,” Journal of Neuroscience Research, vol. 86, no. 16, pp. 3548–3555, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. Y. Guan, K. S. Shindler, P. Tabuena, and A. M. Rostami, “Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice,” Journal of Neuroimmunology, vol. 178, no. 1-2, pp. 40–48, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. L. J. Balcer, S. L. Galetta, P. A. Calabresi et al., “Natalizumab reduces visual loss in patients with relapsing multiple sclerosis,” Neurology, vol. 68, no. 16, pp. 1299–1304, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Dutt, P. Tabuena, E. Ventura, A. Rostami, and K. S. Shindler, “Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis,” Investigative Ophthalmology & Visual Science, vol. 51, no. 3, pp. 1439–1445, 2010. View at Google Scholar · View at Scopus
  28. R. Diem, M. Hobom, K. Maier et al., “Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway,” Journal of Neuroscience, vol. 23, no. 18, pp. 6993–7000, 2003. View at Google Scholar · View at Scopus
  29. M. Nakamura, T. Nakazawa, H. Doi et al., “Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, pp. 1777–1785, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. E. García-Martín, V. Pueyo, J. Fernández et al., “Effect of treatment in loss of retinal nerve fibre layer in multiple sclerosis patients,” Archivos de la Sociedad Espanola de Oftalmologia, vol. 85, no. 6, pp. 209–214, 2010. View at Publisher · View at Google Scholar · View at PubMed
  31. X. Qi, A. S. Lewin, L. Sun, W. W. Hauswirth, and J. Guy, “Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis,” Investigative Ophthalmology & Visual Science, vol. 48, no. 2, pp. 681–691, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus